Daily Pharma News - 2 October 2026

Supreme Court Seeks 16% MRP Cap on Medicines, Flags Huge Cancer Drug Markups

India's drug pricing debate returned to the country's highest court this week. The Supreme Court of India sharply criticised pharmaceutical companies and retailers over the wide gap between the price-to-retailer and the printed maximum retail price (MRP) of certain cancer medicines, observing that such margins could amount to a fraud on public exchequers and on patients paying out of pocket.

The bench suggested a 16% MRP cap on medicines and posted the matter for hearing on October 12. For pharmacy students, this story is a live case study in pharmaceutical economics and drug price control in India. It sits directly alongside the syllabus concepts of DPCO (Drugs Price Control Order) 2013, the National Pharmaceutical Pricing Authority (NPPA), trade margins, and the ethical responsibilities of pharmacists in dispensing and counselling. If the court follows through, it could reshape how oncology drug pricing and trade margins are regulated across the Indian market.

Government Extends Minimum Import Price (MIP) Cover on ATS-8 and Sulfadiazine APIs Till November

The Directorate General of Foreign Trade (DGFT) has extended the minimum import price on two active pharmaceutical ingredient inputs - ATS-8, an atorvastatin intermediate, at $111 per kg, and Sulfadiazine at Rs 1,774 per kg - beyond September 30. The MIP shield protects domestic API manufacturers from cheap imports, with exemptions continuing for special economic zones and export-oriented projects.

This is an important development for students of pharmaceutical industry and management. India has been working to reduce its dependence on imported APIs and intermediates through the Production Linked Incentive (PLI) scheme and trade measures like MIP. Understanding how minimum import prices, import licensing, and SEZ exemptions interact gives a practical window into India's API self-reliance strategy and the economics of bulk drug manufacturing.

Zydus Chairman Pankaj Patel Urges India to Join ICH and Restore Weighted R&D Tax Deduction

At the Bharat Life Sciences Awards, Zydus Lifesciences chairman Pankaj Patel called on India to become a full member of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) and to restore weighted tax deductions for pharmaceutical research and development. He argued for predictable regulation and expedited pathways for breakthrough therapies to make India a genuine innovation hub.

This story connects directly with regulatory affairs and pharmaceutical jurisprudence studies. ICH membership would mean Indian regulations aligning with global standards for clinical trials, good clinical practice, and dossier submissions - a major shift from India's current observer-adjacent position. For students, it is worth revising what ICH guidelines cover (Q series for quality, S series for safety, E series for efficacy) and how weighted R&D deductions historically encouraged domestic innovation in the industry.

Amneal and Macleods Pharmaceuticals Recall Exenatide and Olanzapine in the US

According to the US Food and Drug Administration's enforcement report, two Indian companies initiated recalls in the American market. Amneal Pharmaceuticals recalled 5,694 exenatide pens manufactured in Ahmedabad over a possible defect that could result in no medication being delivered, classified as a Class II recall. Macleods Pharmaceuticals recalled 22,032 bottles of olanzapine tablets after impurity specification failures, classified as a Class III recall.

Recalls are a core concept in pharmaceutical quality assurance, good manufacturing practice (GMP), and the USFDA's enforcement framework. A Class II recall signals a situation where the product may cause temporary or reversible harm, while Class III involves a product unlikely to cause adverse health consequences - a distinction every pharmacy student should know. For Indian exporters, the episode is a reminder of how tightly the USFDA monitors manufacturing plants in Ahmedabad and across India, and why current good manufacturing practice compliance is non-negotiable for export markets.

Russia Registers Domestic Birch-Pollen Allergy Vaccine Allergarda

Russia's Ministry of Health has registered Allergarda, a domestically developed recombinant vaccine for birch pollen allergy that is built on non-allergenic components rather than whole allergen extracts. The registration marks a step forward in allergen-specific immunotherapy, a field that is steadily moving from crude extracts toward precisely engineered recombinant products.

Allergy and immunology products feature in pharmacology and biotechnology curricula, and this development is a good prompt to revise the mechanisms of allergen immunotherapy - subcutaneous and sublingual routes, the shift from Th2 to regulatory T-cell responses, and the difference between symptomatic anti-allergy drugs and disease-modifying desensitisation. Russia's push for domestic biopharmaceutical products also mirrors the broader global trend of countries building indigenous vaccine and biologics capacity.

FDA Approves Camzyos (Mavacamten) for Children With Obstructive Hypertrophic Cardiomyopathy

The US FDA has expanded the approval of Camzyos (mavacamten), a first-in-class cardiac myosin inhibitor, to children weighing 30 kg or more with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). This makes it the first disease-targeted therapy approved for adolescents with oHCM, with the expansion supported by data from the Phase III SCOUT-HCM trial.

Mavacamten is a landmark example of targeted cardiovascular pharmacology - it reduces excessive myosin-actin cross-bridge formation, addressing the underlying hypercontractility of hypertrophic cardiomyopathy rather than merely relieving symptoms. Pharmacy students studying cardiovascular pharmacology should note its mechanism, its place relative to beta blockers and calcium channel blockers in oHCM management, and the broader trend of paediatric label expansions based on dedicated clinical trials.

FDA Accepts Fenebrutinib NDA Under Priority Review for Relapsing and Primary Progressive Multiple Sclerosis

The FDA has accepted Genentech's New Drug Application for fenebrutinib, an oral noncovalent Bruton's tyrosine kinase (BTK) inhibitor, for both relapsing and primary progressive multiple sclerosis under priority review. It is the first BTK inhibitor accepted for both forms of the disease, and Phase III data showed it reduced relapse rates by approximately 51 to 59 percent compared with teriflunomide.

BTK inhibitors represent a new frontier in neuroimmunology, targeting both B-cell activation and microglial inflammation behind the blood-brain barrier. For students of medicinal chemistry and pharmacology, fenebrutinib's noncovalent binding mode is a notable design feature, distinguishing it from earlier covalent BTK inhibitors and potentially offering a different safety profile. A priority review designation also signals that the FDA views the application as a potentially significant advance - a useful case study in regulatory review pathways.

Conclusion

Today's news spans the full arc of a pharmacy student's education. From the Supreme Court's scrutiny of cancer drug pricing and DGFT's API import protections to Zydus chairman Pankaj Patel's call for ICH membership, the Indian stories show regulation, industry policy, and innovation moving together. The US recalls of exenatide and olanzapine underline why quality assurance and GMP matter far beyond the classroom, while the global stories - Russia's Allergarda vaccine, Camzyos for paediatric oHCM, and fenebrutinib for multiple sclerosis - showcase how recombinant biotechnology and targeted small-molecule design are reshaping therapy. For pharmacy students, each of these developments maps onto a syllabus topic: drug pricing, regulatory affairs, quality control, immunology, cardiovascular pharmacology, and neuropharmacology. Staying current with such news is not extra reading - it is how textbook concepts come alive.

References

← All daily news